{"title":"Deucravacitinib for moderate to severe plaque psoriasis","authors":"Steve Chaplin","doi":"10.1002/psb.2089","DOIUrl":null,"url":null,"abstract":"Deucravacitinib (Sotyktu) is a new small‐molecule TYK2 inhibitor for the treatment of adults with moderate to severe plaque psoriasis. This article outlines its mode of action, efficacy and place in therapy.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Deucravacitinib (Sotyktu) is a new small‐molecule TYK2 inhibitor for the treatment of adults with moderate to severe plaque psoriasis. This article outlines its mode of action, efficacy and place in therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
